Presentations & Publications

igm-news-hero-03

Presentations & Publications

IGM-8444 as a potent agonistic Death Receptor 5 (DR5) IgM antibody: Induction of tumor cytotoxicity, combination with chemotherapy and in vitro safety profile.

ASCO20 Virtual Scientific Program – May 29-31, 2020 Poster Session: Developmental Therapeutics–Molecularly Targeted Agents and Tumor Biology Abstract # 3595

Read More...

Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323)

ASCO20 Virtual Scientific Program – May 29-31, 2020 Session: Developmental Therapeutics–Immunotherapy Abstract # e15007

Read More...

IGM-2323: High Avidity IgM-based CD20xCD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

American Society of Hematology Annual Meeting, Orlando, FL – December 7-10, 2019

Read More...

Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies

PEGS Europe – November, 2019

Read More...

Multimeric IgM antibodies targeting DR5 are potent and rapid inducers of tumor cell apoptosis and cell death in vitro and in vivo

AACR Annual Meeting – March, 2019

Read More...

Agonistic IgM Antibodies Targeting Immunostimulatory TNFRSF Members GITR and OX40 Enhance Immune Responses beyond that of IgGs

SITC – November, 2018

Read More...

Multimeric Anti-DR5 IgM antibody displays potent cytotoxicity in vitro and promotes tumor regression in vivo

AACR Annual Meeting – April 1-5, 2017

Read More...

High Avidity Anti-CD20 IgM Antibody for Enhanced Complement-Dependent Cell Killing of Low CD20 Expressing Tumor Cells

PEGS – April, 2016

Read More...

IGM-55.5, a novel monoclonal human recombinant IgM antibody with potent activity against B cell leukemia and lymphoma

AACR Annual Meeting – April 5-9, 2014

Read More...